Choice of treatment in erectile dysfunction associated with hypogonadism
- 作者: Alyaev Y.G1, Vinarov AZ1, Akhvlediani ND1, Alyaev Y.G1, Vinarov AZ1, Akhvlediani ND1
-
隶属关系:
- 期: 编号 4 (2010)
- 页面: 37-42
- 栏目: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277773
- ID: 277773
如何引用文章
全文:
详细
A study was made in the urological clinic of I.M. Sechenov Moscow Medical Academy with participation of 96 patients (mean age 48.24±9.19 years) with erectile dysfunction (ED) associated with hypogonadism. The patients were divided into three groups. Group 1 (n = 30) received 1 intramuscular injection of testosterone undecanoate. Group 2 (n = 34) received on-demand monotherapy with vardenafil for 6 weeks. Group 3 (n = 32) received combined treatment with the above modalities in the same doses and duration. Before and 6 weeks after treatment the patients responded to IIEF-5 questionnaire. All the patients showed a significant improvement of the erectile function. Overall AMS score after the treatment rose more in patients of groups 1 and 3 (p < 0.001). In group 2 the changes were weaker but significant (p = 0.005). The domain of psychological AMS symptoms reduced insignificantly after treatment in group 2 (p = 0.535), but significantly in groups 1 and 3, respectively (p = 0.013 vs p = 0.001). Androgenic deficiency regressed in groups 1 and 3 but enhanced in group 2 (p = 0.001). Domain of sexual symptoms of the AMS scale reduced more significantly in patients of groups 2 and 3 (p < 0.001). Percentage of patients satisfied with the treatment results was 68.85, 70,6 and 90,6% in groups 1, 2 and 3, respectively. Thus, combined treatment of erectile dysfunction in patients with hypogonadism (parenteral testosterone undecanoate and vardenafil) is more effective than monotherapy with androgen-containing drugs or inhibitors of phosphodiesterase of type 5.
参考
- Lue T., Rosen R., Giuliano F. et al., eds. Sexual dysfunctions in men and women.: Health Publications Ltd.; 2004. 37-72, 614-619.
- Rosen R. C., Fisher W. A., Eardley I. et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr. Med. Res. Opin. 2004; 20(5): 607-617.
- Theodoraki A., Bouloux P. M. Testosterone therapy in men. Menopause Int. 2009; 15 (2): 87-92.
- Nasser M. Does testosterone have a role in erectile function? Am. J. Med. 2006; 119: 373-382.
- Traish A. M., Goldstein I., Kim N. N. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur. Urol. 2007; 52 (1): 54-70.
- Shabsigh R., Kaufman J. M., Steidle C., Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. (Baltimore) 2008; 179 (5, Suppl.): S97-S102.
- Guay A. T., Perez J. B., Jacobson J., Newton R. A. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J. Androl. 2001; 22: 793-797.
- Jain P., Rademaker A., McVary K. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J. Urol. (Baltimore). 2000; 164: 371-375.
- Гамидов С. И. Эректильная дисфункция у больных с метаболическим синдромом: патогенез, прогнозирование, диагностика, лечение и профилактика: Дис. ... д-ра мед. наук. М.; 2007.
- Jiann B. P., Yu C. C., Su C. C., Tsai J. Y. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int. J. Impot. Res. 2006; 18 (2): 146-149.
- Valiquette L., Montorsi F., Hellstrom W. J. et al. Penetration and maintenance of erection with vardenafil: a time-from-dosing analysis. Can. J. Urol. 2005; 12 (3): 2687-2698.
补充文件
![](/img/style/loading.gif)